We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.47B
AUM Growth
-$458M
Cap. Flow
+$15.5M
Cap. Flow %
0.35%
Top 10 Hldgs %
43.81%
Holding
163
New
19
Increased
16
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$65.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$64M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$58.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$56.3M
5
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$43.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$65.4M
2
XLRN
Acceleron Pharma
XLRN
+$52.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$38.8M
4
SEER icon
Seer Inc
SEER
+$28.8M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82%
2 Consumer Discretionary 6.51%
3 Financials 0.67%
4 Consumer Staples 0.51%
5 Materials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMGA
26
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$42.9M 0.96%
+2,273,530
New +$43.6M
SDGR icon
27
Schrodinger
SDGR
$1.13B
$38.3M 0.86%
700,000
-97,445
-12% -$6.24M
SWTX
28
DELISTED
SpringWorks Therapeutics
SWTX
$38.1M 0.85%
600,000
+100,000
+20% +$7.71M
MRK icon
29
CALL
Merck
MRK
$325B
$37.6M 0.84%
+500,000
New +$38M
ALXO icon
30
ALX Oncology
ALXO
$261M
$36.9M 0.83%
500,000
– –
NTLA icon
31
Intellia Therapeutics
NTLA
$1.5B
$36.9M 0.83%
275,000
+25,000
+10% +$3.79M
VRTX icon
32
CALL
Vertex Pharmaceuticals
VRTX
$124B
$36.3M 0.81%
+200,000
New +$39M
BLU
33
DELISTED
BELLUS Health Inc.
BLU
$32.2M 0.72%
5,250,000
+500,000
+11% +$1.9M
GOSS icon
34
Gossamer Bio
GOSS
$92M
$29.7M 0.66%
2,358,968
– –
AGEN
35
Agenus
AGEN
$276M
$28.9M 0.65%
280,225
-25,475
-8% -$2.88M
TRML
36
DELISTED
Tourmaline Bio
TRML
$28M 0.63%
206,426
– –
KRON
37
DELISTED
Kronos Bio
KRON
$27.6M 0.62%
1,317,954
– –
ATRA icon
38
Atara Biotherapeutics
ATRA
$69.8M
$26.9M 0.6%
60,000
– –
ITOS
39
DELISTED
iTeos Therapeutics
ITOS
$26.8M 0.6%
994,047
– –
REPL icon
40
Replimune Group
REPL
$430M
$26.7M 0.6%
900,000
– –
TGTX icon
41
TG Therapeutics
TGTX
$8.15B
$26.6M 0.6%
800,000
– –
PTGX icon
42
Protagonist Therapeutics
PTGX
$8.67B
$26.6M 0.59%
+1,500,000
New +$64M
KRYS icon
43
Krystal Biotech
KRYS
$10.6B
$26.1M 0.58%
500,000
– –
DNLI icon
44
Denali Therapeutics
DNLI
$3.75B
$25.2M 0.56%
500,000
– –
FHTX icon
45
Foghorn Therapeutics
FHTX
$279M
$24M 0.54%
1,720,720
– –
KYMR icon
46
Kymera Therapeutics
KYMR
$8.65B
$23.5M 0.53%
400,000
+150,000
+60% +$8.7M
TPTX
47
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$23.3M 0.52%
350,000
– –
FMTX
48
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$23.2M 0.52%
1,000,000
– –
SQZ
49
DELISTED
SQZ Biotechnologies Company
SQZ
$23.2M 0.52%
1,606,309
– –
OTLY
50
Oatly Group
OTLY
$480M
$22.7M 0.51%
75,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2021 Portfolio in Review

As of Q3 2021, Artal Group held 163 positions worth $4.47B, down 9.3% from $4.93B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q3 2021 filing shows 19 new, 16 increased, 16 reduced and 17 closed positions. Its largest new stake was Erasca: 3,172,221 shares worth $67.3M. The largest sale was BeOne Medicines Ltd, an estimated $65.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q3 2021 buy was Erasca: 3,172,221 shares worth $67.3M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $56.3M increase.
  • Artal Group's biggest Q3 2021 reduction was BeOne Medicines Ltd, cutting an estimated $65.4M.
  • Artal Group fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021, selling an estimated $38.8M.
  • Artal Group's ten largest holdings make up 44% of its $4.47B portfolio in Q3 2021.
  • Artal Group opened 19 new positions and closed 17 in Q3 2021.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $4.47B.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.